F2R and breast carcinoma: Densitometric quantification of PAR1-immunoreactive bands indicated that 20 of the 29 patients (69%) overexpressed PAR1 by more than 70% (Figure 1a and 1b) of that expressed by a mock exposed invasive breast cancer cell line (previously described in methods, data not shown).